Online inquiry

IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3040MR)

This product GTTS-WQ3040MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3040MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4078MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ1977MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ9907MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ10899MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ13977MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ4259MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ1029MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ5904MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW